Research Interests:
- Role of organic cation transporters in chemotherapy-induced toxicity
- Mechanisms of drug-drug interactions
- Clinical pharmacology of anticancer agents
Dr. Sparreboom’s research studies the contribution of organic cation transporters to chemotherapy-induced toxicity profiles, identifies chemical inhibitors of critical transporters, translates the findings to clinical trials in collaboration with scientists and oncologists, and ultimately aims to improve the long-term outcome of patients with cancer by modulating the therapeutic window of widely-used chemotherapeutics. His research currently focuses on the development of transport modulators that could be used in conjunction with platinum-based drugs and anthracyclines, with emphasis on the development of innovative preclinical model systems.
Biosketch:
Dr. Sparreboom received his PhD degree from Utrecht University, the Netherlands. He was a staff scientist at the National Cancer Institute then an Associate Member in the Department of Pharmaceutical Sciences at St. Jude Children’s Research Hospital before moving to The Ohio State University (OSU) in 2015. Dr. Sparreboom is Professor of Pharmaceutics and Pharmacology, the Lucius A. Wing Chair of Cancer Research and Therapy, and a member of the Translational Therapeutics Program at the OSU Comprehensive Cancer Center. He has authored over 390 peer-reviewed articles in well-respected journals such as Clinical Cancer Research, Journal of Clinical Investigation and Proceedings of the National Academy of Sciences USA. He is the co-holder of several U.S., European and world patents. He has served on multiple NIH Study Section and Review Panels, including the NCI Experimental Therapeutics (NExT) Program since 2009, and in 2021 became a chartered member of the the Xenobiotic and Nutrient Disposition and Action [XNDA] Study Section at the NIH. He has held editorial board appointments with various journals such as the Journal of Clinical Oncology, and has served as Senior Editor of Clinical Cancer Research (2008-present) and Associate Editor of Clinical Pharmacology & Therapeutics (2008-2018). Additionally, he has shared his research in over 100 presentations to various organizations, including the American Association for Cancer Research, the American Society for Clinical Pharmacology and Therapeutics and the American Society of Clinical Oncology. Dr. Sparreboom has mentored over 30 postdoctoral PhD researchers and graduate and undergraduate students, with many of them now holding prominent positions at academic institutions and in industry.
Trainees:
Kevin Huang- Postdoctoral Scholar
Thomas Drabison – Graduate Student
Mike Boeckman – Graduate Student
Levi Steenrod -Undergraduate
Recent Publications:
Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O’Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM. DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23. (IF, 50.739)
Li Y, Drabison T, Nepal M, Ho RH, Leblanc AF, Gibson AA, Jin Y, Yang W, Huang KM, Uddin ME, Chen M, DiGiacomo DF, Chen X, Razzaq S, Tonniges JR, McTigue DM, Mims AS, Lustberg MB, Wang Y, Hummon AB, Evans WE, Baker SD, Cavaletti G, Sparreboom A, Hu S. Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy. JCI Insight. 2023 Jul 24;8(14):e164646. doi: 10.1172/jci.insight.164646. (IF, 8.04)
Persaud AK, Bernier MC, Massey MA, Agrawal S, Kaur T, Nayak D, Xie Z, Weadick B, Raj R, Hill K, Abbott N, Joshi A, Anabtawi N, Bryant C, Somogyi A, Cruz-Monserrate Z, Amari F, Coppola V, Sparreboom A, Baker SD, Unadkat JD, Phelps MA, Govindarajan R. Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice. Nat Commun. 2023 Jun 1;14(1):3175. doi: 10.1038/s41467-023-38789-8. (IF, 16.6)
Talebi Z, Jin Y, Baker SD, Addison D, Sparreboom A. Determination and disposition of meta-iodobenzylguanidine in plasma and heart of transporter-deficient mice by UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 May 1;1222:123699. doi: 10.1016/j.jchromb.2023.123699. Epub 2023 Apr 7. (IF, 3.318)
Anabtawi N, Drabison T, Hu S, Sparreboom A, Talebi Z. The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature. Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):459-468. doi: 10.1080/17425255.2022.2113380.
Anderson JA, Huang KM, Lustberg MB, Sparreboom A, Hu S. Solute carrier transportome in chemotherapy-induced adverse drug reactions. Rev Physiol Biochem Pharmacol. 2022;183:177-215. doi: 10.1007/112_2020_30.
Eisenmann ED, Talebi Z, Sparreboom A, Baker SD. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Basic Clin Pharmacol Toxicol. 2022 Jan;130 Suppl 1(Suppl 1):23-35. doi: 10.1111/bcpt.13623. Epub 2021 Jun 28.
Eisenmann ED, Garrison DA, Talebi Z, Jin Y, Silvaroli JA, Kim J-G, Sparreboom A, Savona MR, Mims AS, Baker SD. Interaction of antifungal drugs with CYP3A-and OATP1B-mediated venetoclax elimination. Pharmaceutics. 2022 Mar 23;14(4):694. doi: 10.3390/pharmaceutics14040694.
Garrison DA, Jin Y, Talebi Z, Hu S, Sparreboom A, Baker SD, Eisenmann ED. Itraconazole-induced increases in gilteritinib exposure are mediated by CYP3A and OATP1B. Molecules. 2022 Oct 12;27(20):6815. doi: 10.3390/molecules27206815.
Hafey MJ, Aleksunes LM, Bridges CC, Brouwer KR, Chien H-C, Leslie EM, Hu S, Li Y, Shen J, Sparreboom A, Sprowl JA, Tweedie D, Lai Y. Transporters and toxicity: insights from the International Transporter Consortium workshop 4. Clin Pharmacol Ther. 2022 Sep;112(3):527-539. doi: 10.1002/cpt.2638.
Jin Y, Li Y, Eisenmann ED, Figg WD, Baker SD, Sparreboom A, Hu S. Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Nov 1;1210:123437. doi: 10.1016/j.jchromb.2022.123437.
Li Y, Jin Y, Taheri H, Schmidt KT, Gibson AA, Buck SAJ, Eisenmann ED, Mathijssen RHJ, Figg WD, Baker SD, Sparreboom A, Hu S. A Metabolomics approach for predicting OATP1B-Type transporter-mediated drug-drug interaction liabilities. Pharmaceutics. 2022 Sep 13;14(9):1933. doi: 10.3390/ pharmaceutics14091933.
Nepal MR, Taheri H, Li Y, Uddin ME, Jin Y, DiGiacomo DF, Gibson AA, Lustberg MB, Hu S, Sparreboom A. Targeting OCT2 with duloxetine to prevent oxaliplatin-induced peripheral neurotoxicity. Cancer Res Commun. 2022 Nov;2(11):1334-1343. doi: 10.1158/2767-9764.crc-22-0172.
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in targeted therapy and supportive care therapies for cancer. Methods Mol Biol. 2022;2547:47-61. doi: 10.1007/978-1-0716-2573-6_3.
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in cytotoxic chemotherapy of cancer. Methods Mol Biol. 2022;2547:63-94. doi: 10.1007/978-1-0716-2573-6_4.
Uddin ME, Eisenmann ED, Huang KM, Garrison DA, Talebi Z, Gibson AA, Jin Y, Nepal M, Bonilla IM, Fu Q, Miller A, Tarasovc M, Jay CE, Cui X, Einolf HJ, Pelise RM, Smith S, Radwanski P, Sweet DH, König J, Fromm MF, Carnes CA, Hu S, Sparreboom A. MATE1 deficiency exacerbates dofetilide-induced proarrhythmia. Int J Mol Sci. 2022 Aug 3;23(15):8607. doi.org/10.3390/ijms23158607.